Herpes and Shingles References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Kasper DL, Braunwald E, et al, eds. Harrison's Principles of Internal Medicine . 16th ed. New York , NY : McGraw-Hill; 2004.
  2. Crumpacker CS. Cytomegalovirus. In: Mandell GL, Bennett JE, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases . 5th ed. Philadelphia , Pa : Churchill Livingstone; 2000:127.
  3. Straus SE. Human herpesvirus types 6 and 7. In: Mandell GL, Bennett JE, et al, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, PA: Churchill Livingstones; 2000.
  4. Straus SE. Human herpesvirus types 6 and 7. In: Mandell GL, Bennett JE, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia , PA: Churchill Livingstone; 2000a:129.
  5. Schulz TF, Moore PS. Kaposi's sarcoma-associated herpesvirus: a new human tumor virus, but how? Trends Microbiol. 1999 May;7(5):196-200.
  6. Straus SE. Human herpesvirus type 8 (Kaposi's sarcoma-associated herpesvirus). In: Mandell GL, Bennett JE, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia , PA: Churchill Livingstone; 2000b:130.
  7. Mesri EA, Cesarman E, et al. Human herpesvirus-8/Kaposi's sarcoma-associated herpesvirus is a new transmissible virus that infects B cells. J ExpMed . 1996 May 1;183(5):2385-90.
  8. Moore PS.The emergence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8).N Engl J Med . 2000 Nov 9;343(19):1411-3.
  9. Sarid R, Olsen SJ, et al. Kaposi's sarcoma-associated herpesvirus: epidemiology, virology, and molecular biology. Adv Virus Res . 1999;52:139-232.
  10. Niedobitek G, Agathanggelou A, et al. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol. 1997 Jun;182(2):151-9.
  11. Zhou F, Harpaz R, et al. Impact of varicella vaccination on health care utilization. JAMA . 2005 Aug 17;294(7):797-802.
  12. Jumaan AO, Yu O, et al. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella: 1992-2002. J Infect Dis . 2005 Jun 15;191(12):2002-7.
  13. OxmanMN , Levin MJ, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.N Engl J Med . 2005 Jun 2;352(22):2271-84.
  14. Wilkerson MG, Jordan WP, et al. Herpes zoster as a sign of AIDS-related complex.Am Fam Physician. 1987 Oct;36(4):233-5.
  15. Cunningham AL ,Dworkin RH. The management of post-herpetic neuralgia.BMJ . 2000 Sep 30;321(7264):778-9.
  16. Liesegang TJ. The varicella-zoster virus: systemic and ocular features. J Am AcadDermatol. 1984 Aug;11(pt 1):165-91.
  17. Liesegang TJ. Herpes zoster virus infection.CurrOpinOphthalmol. 2004 Dec;15(6):531-6.
  18. Ostler HB.The management of ocular herpesvirus infections.SurvOphthalmol. 1976 Sep-Oct;21(2):136-4709ENG.
  19. Schmader K. Herpes zoster in older adults.Clin Infect Dis . 2001 May 15;32(10):1481-6.
  20. Weinhoff ML. Herpes zoster ophthalmicus.Ophthalmic Semin. 1976;1(3):227-52.
  21. Johnson RW. Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes.2003 Aug;10(2):38-45.
  22. Baldessarini RJ. Chapter 19: Drugs and the treatment of psychiatric disorders: depression and anxiety disorders. In: Hardman JG, Limbird LE, eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics. 10th ed. New York , NY : McGraw-Hill; 2001.
  23. Sra KK, Tyring SK. Treatment of postherpetic neuralgia. Skin Therapy Letter.Vol 9.No.8. October 2004. Available at: http://www.skintherapyletter.com/tf/content.asp?a=2466 .Accessed September 30, 2005.
  24. Kumar A. Cimetidine: an immunomodulator. DICP. 1990 Mar;24(3):289-295.
  25. Miller A, Harel D, et al. Cimetidine as an immunomodulator in the treatment of herpes zoster. J Neuroimmunol. 1989 Mar;22(1):69-76.
  26. Kapinska-Mrowiecka M, Turowski G. Efficacy of cimetidine in treatment of herpes zoster in the first 5 days from the moment of disease manifestation. Pol TygLek. 1996 Jun;51(23-26):338-9.
  27. van der Spuy S, Levy DW, et al. Cimetidine in the treatment of herpesvirus infections. S Afr Med J . 1980 Jul 19;58(3):112-6.
  28. Hayne ST, Mercer JB. Herpes zoster: treatment with cimetidine. Can Med Assoc J. 1983 Dec 15;129(12):1284-5.
  29. Tyler I. Herpes simplex type 2 virus: a new horizon. ABNF J. 2005 May-Jun;16(3):63-4.
  30. Jones CA, Cunningham AL. Development of prophylactic vaccines for genital and neonatal herpes.Expert Rev Vaccines . 2003 Aug;2(4):541-9.
  31. Stanberry LR. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines.Herpes.2004 Aug;11(suppl 3):161A-169A.
  32. Isada CM, Kasten BL Jr, et al, eds. Infectious Diseases Handbook. 5th ed. Lexi-Comp; 2003.
  33. Murray PR, Rosenthal KS , et al. In: Mims CP, Playfair J, et al. Medical Microbiology . 4th ed. St Louis , Mo : Mosby; 2002.
  34. Bhaskaram P. Immunobiology of mild micronutrient deficiencies.Br J Nutr. 2001 May;85(suppl 2):S75-S80.
  35. Elmadfa I, Bartens C, et al. Nutritional status and the immune system: fat-soluble vitamins and other nutrients. BiblNutrDieta.1994;(51):136-41.
  36. Grimble RF. Effect of antioxidative vitamins on immune function with clinical applications.Int J VitamNutrRes . 1997;67(5):312-20.
  37. Sheridan J, Kern E, et al. Evaluation of antioxidant healing formulations in topical therapy of experimental cutaneous and genital herpes simplex virus infections. Antiviral Res . 1997 Dec;36(3):157-66.
  38. Mostad SB, Kreiss JK, et al. Cervical shedding of herpes simplex virus in human immunodeficiency virus-infected women: effects of hormonal contraception, pregnancy, and vitamin A deficiency. J Infect Dis . 2000 Jan;181(1):58-63.
  39. Pomponi F, Cariati R, et al. Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood . 1996 Oct 15;88(8):3147-59.
  40. Meisenberg G, Simmons WH. Principles of Medical Biochemistry. St Louis , Mo : Mosby; 1998.
  41. Santos MS, Meydani SN, et al. Natural killer cell activity in elderly men is enhanced by beta-carotene supplementation. Am J ClinNutr.1996 Nov;64(5)772-7.
  42. Li W, Zheng T, et al. Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascular smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence. Brain Res Bull. 2001 Jan 1;54(1):83-9.
  43. De Souza MC, Walker AF, et al. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med. 2000 Mar;9(2):131-9.
  44. Terezhalmy GT, Bottomley WK, et al. The use of water-soluble bioflavonoid-ascorbic acid complex in the treatment of recurrent herpes labialis.Oral Surg Oral Med Oral Pathol. 1978 Jan;45(1):56-62.
  45. Hovi T, Hirvimies A, et al. Topical treatment of recurrent mucocutaneous herpes with ascorbic acid-containing solution. Antiviral Res . 1995 Jun;27(3):263-70.
  46. Chan AC. Partners in defense, vitamin E and vitamin C.Can J PhysiolPharmacol. 1993 Sep;71(9):725-31.
  47. Meydani M, Meisler JG. A closer look at vitamin E: can this antioxidant prevent chronic diseases? Postgrad Med . 1997 Aug;102(2):199-201, 206-7.
  48. Cuevas LE, Koyanagi A. Zinc and infection: a review. Ann Trop Paediatr. 2005 Sep;25(3):149-60.
  49. Godfrey HR, Godfrey NJ, et al. A randomized clinical trial on the treatment of oral herpes with topical zinc oxide/glycine.AlternTher Health Med . 2001 May-Jun;7(3):49-56.
  50. Chandra RK. Effect of vitamin and trace-element supplementation on immune responses and infection in elderly subjects.Lancet.1992 Nov 7;340(8828):1124-7.
  51. Girodon F, Lombard M, et al. Effect of micronutrient supplementation on infection in institutionalized elderly subjects: a controlled trial. Ann NutrMetab. 1997;41(2):98-107.
  52. Flodin NW. The metabolic roles, pharmacology, and toxicology of lysine.J Am CollNutr. 1997 Feb;16(1):7-21.
  53. Marcason W. Will taking the amino acid supplement lysine prevent or treat the herpes simplex virus? J Am Diet Assoc. 2003 Mar;103(3):351.
  54. Griffith RS, Walsh DE , et al. Success of L-lysine therapy in frequently recurrent herpes simplex infection: treatment and prophylaxis. Dermatologica. 1987;175(4):183-90.
  55. McCune MA, Perry HO, et al. Treatment of recurrent herpes simplex infections with L-lysine monohydrochloride. Cutis . 1984 Oct;34(4):366-73.
  56. Thein DJ, Hurt WC. Lysine as a prophylactic agent in the treatment of recurrent herpes simplex labialis.Oral Surg Oral Med Oral Pathol. 1984 Dec;58(6):659-66.
  57. Balch PA, Balch JF. Prescription for Nutritional Healing . 3rd ed. Garden City Park , NY : Avery; 2000.
  58. Jamison JR. Clinical Guide to Nutrition and Dietary Supplements in Disease Management .Philadelphia , Pa : Churchill Livingstone; 2004.
  59. Huleihel M, Isanu V. Anti-herpes simplex virus effect of an aqueous extract of propolis. Isr Med AssocJ . 2002 Nov;4(11):923-7.
  60. Vynograd N, Vynograd I, et al. A comparative multi-centre study of the efficacy of propolis, acyclovir and placebo in the treatment of genital herpes (HSV).Phytomedicine. 2000 Mar;7(1):1-6.
  61. Corey L. Herpes simplex virus. In: Mandell GL, Bennett JE, et al, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases . 5th ed. Philadelphia , Pa : Churchill Livingstone; 2000:125.
  62. Aiuti F, Sirianni MC, et al. A placebo-controlled trial of thymic hormone treatment of recurrent herpes simplex labialis infection in immunodeficient host: results after a 1-year follow-up. ClinImmunolImmunopathol. 1984 Jan;30(1):11-8.
  63. Andersen JH, Jenssen H, et al. Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparansulphate at the cell surface. J Med Virol. 2004 Oct;74(2):262-71.
  64. Wakabayashi H, Kurokawa M, et al. Oral lactoferrin prevents body weight loss and increases cytokine responses during herpes simplex virus type 1 infection of mice. BiosciBiotechnolBiochem. 2004 Mar;68(3):537-44.
  65. Andersen JH, Jenssen H, et al. Lactoferrin and lactoferricin inhibit herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res . 2003 May;58(3):209-15.
  66. Fujihara T, Hayashi K. Lactoferrin inhibits herpes simplex virus type-1 (HSV-1) infection to mouse cornea. Arch Virol. 1995;140(8):1469-72.
  67. Kutluay SB, Doroghazi J, Roemer ME, Triezenberg SJ. Curcumin inhibits herpes simplex virus immediate-early gene expression by a mechanism independent of p300/CBP histone acetyltransferase activity. Virology. 2008 Apr 10;373(2):239-47.
  68. Hayashi K, Nakano T, Hashimoto M, Kanekiyo K, Hayashi T. Defensive effects of a fucoidan from brown alga Undariapinnatifida against herpes simplex virus infection. IntImmunopharmacol. 2008 Jan;8(1):109-16.
  69. Maruyama H, Tanaka M, Hashimoto M, Inoue M, Sasahara T. The suppressive effect of Mekabufucoidan on an attachment of Cryptosporidium parvumoocysts to the intestinal epithelial cells in neonatal mice. Life Sci. 2007 Jan 30;80(8):775-81.
  70. Cooper R, Dragar C, Elliot K, Fitton JH, Godwin J, Thompson K. GFS, a preparation of Tasmanian Undariapinnatifida is associated with healing and inhibition of reactivation of Herpes. BMC Complement Altern Med. 2002 Nov 20;2:11.
  71. Lee JB, Hayashi K, Hashimoto M, Nakano T, Hayashi T. Novel antiviral fucoidan from sporophyll of Undariapinnatifida (Mekabu). Chem Pharm Bull (Tokyo). 2004 Sep;52(9):1091-4.
  72. Thompson KD, Dragar C. Antiviral activity of Undariapinnatifida against herpes simplex virus. Phytother Res. 2004 Jul;18(7):551-5.
  73. Chen JH, Lim JD, Sohn EH, Choi YS, Han ET.Growth-inhibitory effect of a fucoidan from brown seaweed Undariapinnatifida on Plasmodium parasites.Parasitol Res. 2009 Jan;104(2):245-50.
  74. Harden EA, Falshaw R, Carnachan SM, Kern ER, Prichard MN. Virucidal activity of polysaccharide extracts from four algal species against herpes simplex virus. Antiviral Res. 2009 Sep;83(3):282-9.
  75. Valenti G. Neuroendocrine hypothesis of aging: the role of corticoadrenal steroids. J Endocrinol Invest. 2004a;27(suppl 6):62-3.
  76. Valenti G, Denti L, et al. Effect of DHEAS on skeletal muscle over the life span: the InCHIANTI study. J Gerontol A BiolSci Med Sci. 2004b May;59(5):466-72.
  77. Khorram O, Vu L, et al. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men. J Gerontol A BiolSci Med Sci. 1997 Jan;52(1):M1-M7.
  78. Danenberg HD, Ben-Yehuda A, et al. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection. Vaccine.1995;13(15):1445-8.
  79. Loria RM, Padgett DA, et al. Regulation of the immune response by dehydroepiandrosterone and its metabolites.J Endocrinol.1996 Sep;150(suppl):S209-S220.
  80. Solerte SB, Fioravanti M, et al. Dehydroepiandrosterone sulfate decreases the interleukin-2-mediated overactivity of the natural killer cell compartment in senile dementia of the Alzheimer type. Dement GeriatrCognDisord. 1999 Jan-Feb;10(1):21-7.
  81. Inserra P, Zhang Z, et al. Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice. ProcSocExpBiol Med. 1998 May;218(1):76-82.
  82. Weber ND, Andersen DO, et al. In vitro virucidal effects of Allium sativum (garlic) extract and compounds. Planta Med. 1992 Oct;58(5):417-23.